TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
BOTHELL, Wash., April 20, 2017 -- Alder BioPharmaceuticals®, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its first quarter 2017 financial and operating results after the close of U.S. financial markets on Thursday, April 27, 2017. Alder management will host a conference call and live audio webcast to discuss the results and provide a general business update at 5:00 p.m. ET the same day.
The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers, and providing conference ID number 94734332. The webcast will be broadcast live on the investors section of Alder’s website at www.alderbio.com and will be available for replay following the call for 30 days.
About Alder BioPharmaceuticals®
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts: David Schull Russo Partners, LLC (212) 845-4271 (646) 942-5627 [email protected] Investor Relations Contact: David Walsey Alder BioPharmaceuticals® Inc. (425) 408-8032 [email protected]
